GlassScriptPhysician profile
Joy Irvin
NPI 1740590140
$3,289.98
in general payments reported to CMS, 2019-2025
25 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $306 · 2022: $246 · 2023: $613 · 2024: $1,068 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,737.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $580.48 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $535.83 | 2021-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $528.35 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $268.00 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $175.95 | 2024-2025 | Gvoke Hypopen |
| Abbvie INC. | $165.03 | 2022-2025 | |
| Esperion Therapeutics, INC. | $140.80 | 2021 | |
| Pfizer INC. | $138.38 | 2023-2025 | |
| Glaxosmithkline, LLC. | $125.05 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.33 | 2022-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $108.95 | 2023-2025 | Voquezna |
| Exact Sciences Corporation | $90.19 | 2024-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $44.09 | 2025 | Zoryve |
| Astellas Pharma US INC | $37.18 | 2023-2024 | Veozah |
| Shield Therapeutics INC | $34.83 | 2023 | Accrufer |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $32.46 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $32.26 | 2023-2024 | Gardasil 9, Gardasil, Capvaxive |
| Abbott Laboratories | $22.58 | 2024 | Amplatzer Amulet |
| Sumitomo Pharma America, INC. | $20.99 | 2024 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $20.93 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.94 | 2024 | Horizant |
| Takeda Pharmaceuticals U.S.A., INC. | $14.21 | 2022 | |
| Currax Pharmaceuticals LLC | $13.90 | 2023 | Contrave |
| Bayer Healthcare Pharmaceuticals INC. | $13.73 | 2025 | |
| Acella Pharmaceuticals, LLC | $13.54 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Irvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.